Cargando…

Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers

BACKGROUND: Alzheimer’s disease (AD) is foremost characterized by β-amyloid (Aβ)-extracellular plaques, tau-intraneuronal fibrillary tangles (NFT), and neuroinflammation, but over the last years it has become evident that peripheral inflammation might also contribute to the disease. AD patients ofte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pocevičiūtė, Dovilė, Nuñez-Diaz, Cristina, Roth, Bodil, Janelidze, Shorena, Giannisis, Andreas, Hansson, Oskar, Wennström, Malin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414424/ https://www.ncbi.nlm.nih.gov/pubmed/36008818 http://dx.doi.org/10.1186/s13195-022-01062-z

Ejemplares similares

Plasma IAPP-Autoantibody Levels in Alzheimer’s Disease Patients Are Affected by APOE4 Status
por: Pocevičiūtė, Dovilė, et al.
Publicado: (2023)

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease
por: Schultz, Nina, et al.
Publicado: (2019)

Contraction of human brain vascular pericytes in response to islet amyloid polypeptide is reversed by pramlintide
por: Nuñez-Diaz, Cristina, et al.
Publicado: (2023)

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease
por: Cullen, Nicholas C, et al.
Publicado: (2023)

Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
por: Wennström, Malin, et al.
Publicado: (2022)

Behavioral and cognitive performance of humanized APOEε3/ε3 liver mice in relation to plasma apolipoprotein E levels
por: Kessler, Kat, et al.
Publicado: (2023)

Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype
por: Janelidze, Shorena, et al.
Publicado: (2017)

Pro-Inflammatory Cytokines Reduce the Proliferation of NG2 Cells and Increase Shedding of NG2 In Vivo and In Vitro
por: Wennström, Malin, et al.
Publicado: (2014)

Blood‐based biomarkers for Alzheimer's disease
por: Leuzy, Antoine, et al.
Publicado: (2021)

Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios
por: Janelidze, Shorena, et al.
Publicado: (2023)

Association of CSF Aβ(38) Levels With Risk of Alzheimer Disease–Related Decline
por: Cullen, Nicholas, et al.
Publicado: (2022)

β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
por: Kumar, Atul, et al.
Publicado: (2022)

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
por: Cicognola, Claudia, et al.
Publicado: (2021)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Towards a unified protocol for handling of CSF before β-amyloid measurements
por: Janelidze, Shorena, et al.
Publicado: (2019)

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2018)

Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease
por: Hall, Sara, et al.
Publicado: (2020)

The implications of different approaches to define AT(N) in Alzheimer disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2020)

Blood pressure variability and medial temporal atrophy in apolipoprotein ϵ4 carriers
por: Sible, Isabel J., et al.
Publicado: (2021)

Longitudinal white matter and cognitive development in pediatric carriers of the apolipoprotein ε4 allele
por: Remer, Justin, et al.
Publicado: (2020)

Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
por: Hall, Sara, et al.
Publicado: (2018)

Serum Neurofilament Light Chain as a Marker of Progression in Parkinson’s Disease: Long-Term Observation and Implications of Clinical Subtypes
por: Ygland Rödström, Emil, et al.
Publicado: (2022)

A genetic signature including apolipoprotein Eε4 potentiates the risk of herpes simplex–associated Alzheimer's disease
por: Lopatko Lindman, Karin, et al.
Publicado: (2019)

The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies
por: Wennström, Malin, et al.
Publicado: (2015)

Apolipoprotein E ε4 allele and malondialdehyde level are independent risk factors for Alzheimer’s disease
por: López-Riquelme, Natividad, et al.
Publicado: (2016)

Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer’s dementia
por: Byman, Elin, et al.
Publicado: (2020)

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
por: Cullen, Nicholas C., et al.
Publicado: (2021)

A FDG-PET Study of Metabolic Networks in Apolipoprotein E ε4 Allele Carriers
por: Yao, Zhijun, et al.
Publicado: (2015)

High Glycemic Load Is Associated with Cognitive Decline in Apolipoprotein E ε4 Allele Carriers
por: Gentreau, Mélissa, et al.
Publicado: (2020)

Apolipoprotein E ε-4 as a genetic determinant of Alzheimer’s disease heterogeneity
por: Kotze, MJ, et al.
Publicado: (2015)

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2020)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
por: Pereira, Joana B., et al.
Publicado: (2022)

CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers
por: Ahmad, Shahzad, et al.
Publicado: (2020)

Amyloid blood biomarker detects Alzheimer's disease
por: Nabers, Andreas, et al.
Publicado: (2018)

Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
por: Pichet Binette, Alexa, et al.
Publicado: (2022)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Increased apolipoprotein E and decreased TNF‐α in the cerebrospinal fluid of nondemented APOE‐ε4 carriers
por: Sasayama, Daimei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_snje541f2ob5osk51ireiienje